Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Dacoltson Feb 22, 2006 6:19pm
264 Views
Post# 10407145

Webcast Update

Webcast UpdateResverlogix Announces Live Web Cast Update 2/22/2006 CALGARY, ALBERTA, Feb 22, 2006 (CCNMatthews via COMTEX) -- Resverlogix Corp. (TSX:RVX) ("Resverlogix"), announced today that it will be hosting a live Vcall web cast on Thursday February 23rd at 11:00am MST. The web cast will allow securities analysts, shareholders and other key stakeholders the opportunity to hear management discuss the company's strategic objectives for 2006 and corporate updates in regards to its ongoing licensing negotiations for its ReVas(TM) program. The call is being webcast by Vcall and can be accessed at a link provided on "Resverlogix's" website at www.resverlogix.com . Investors can also access the webcast at www.InvestorCalendar.com. The web cast will be available on our website for replay throughout 2006. The web cast link will be posted on the Resverlogix web site www.resverlogix.com prior to the event.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities